Outcomes of three different new generation transcatheter aortic valve prostheses
| Autor: | Sergio Buccheri, Emanuela Di Simone, Enrico Criscione, Giuliano Costa, Andrea Picci, Marco Barbanti, Ketty La Spina, Denise Todaro, Marco Nastasi, Corrado Tamburino, Paolo D'Arrigo, Carmelo Sgroi |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Transcatheter aortic medicine.medical_treatment 030204 cardiovascular system & hematology Prosthesis Design Single Center Severity of Illness Index Prosthesis Transcatheter Aortic Valve Replacement 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Risk of mortality Humans Radiology Nuclear Medicine and imaging 030212 general & internal medicine Aged Retrospective Studies Aged 80 and over business.industry Hemodynamics Retrospective cohort study Aortic Valve Stenosis Recovery of Function General Medicine medicine.disease Stenosis Treatment Outcome Cardiothoracic surgery Aortic Valve Heart Valve Prosthesis Cohort Cardiology Female Cardiology and Cardiovascular Medicine business |
| Zdroj: | Catheterization and Cardiovascular Interventions. 95:398-407 |
| ISSN: | 1522-726X 1522-1946 |
| DOI: | 10.1002/ccd.28524 |
| Popis: | AIMS To evaluate outcomes of transfemoral transcatheter aortic valve implantation (TF-TAVI) using three different new-generation devices. BACKGROUND Although new generation transcatheter aortic valves (TAVs) have demonstrated to improve procedural outcomes, to date few head-to-head comparisons are available among these devices. METHODS This is a single center, retrospective study. From September 2014 to February 2018, 389 patients underwent elective TF-TAVI for native, severe aortic stenosis using a new-generation transcatheter aortic valve (TAV) with a preprocedural multi-detector computed tomography assessment. Among these, 346 patients received an Edwards SAPIEN 3 (n = 134), Medtronic Evolut R (n = 111), or Boston ACURATE neo (n = 101) prosthesis. Differences in baseline clinical characteristics between groups were accounted using the propensity score weighting method. RESULTS The mean age for the entire study cohort was 81.4 ± 5.2 years while the Society of Thoracic Surgery predicted risk of mortality was 4.0 ± 2.5%. After propensity score weighting adjustment, TAVs did not differently impact on 30-day all-cause and cardiovascular mortality. Evolut R device showed an increased risk of permanent pacemaker implantation (PPI) after the procedure (8.3% for SAPIEN 3 vs. 16.7% for Evolut R vs. 2.1% for ACURATE neo, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text